Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib
Titel:
Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib
Auteur:
Horinouchi, H. Cho, B.C. Camidge, D.R. Goto, K. Tomasini, P. Li, Y. Vasilopoulos, A. Brunsdon, P. Hoffman, D. Shi, W. Bolotin, E. Blot, V. Goldman, J.